Scholarlink

<p>Starting in 2020, we quantified anti-wildtype SARS-CoV-2 spike sera IgG at monthly intervals from generally healthy adults after various doses of mRNA-based COVID-19 vaccination and in the context of hybrid immunity. Confirmed post-vaccination infections and subclinical infections identified by longitudinal serology were removed from vaccine-only analyses. Over 400 days, the two-dose vaccine-alone antibody response decayed at a half-life (<i>t</i><sub>1/2</sub>) of 59.8 days compared with a <i>t</i><sub>1/2</sub> of 99.7 days after receipt of one booster dose. In the hybrid immunity model, the <i>t</i><sub>1/2</sub> was greater at 241 days. Using cut-offs for correlation of protection obtained in a prior study, we modeled that individuals with hybrid immunity maintain antibody levels above a 75% correlate of immunity for 283 days after an immune-boosting event. These data offer insights into SARS-CoV-2 antibody decay kinetics that may inform COVID-19 vaccine timing in the younger (age under 60), healthy adult population.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Estimating the decay of protective antibodies induced by SARS-CoV-2 mRNA vaccination and hybrid immunity

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年10月29日

查看全文
  • McKenna D. Roe,
  • Si’Ana A. Coggins,
  • Emily S. Darcey,
  • Emilie Goguet,
  • Hannah Haines-Hull,
  • Dominic Esposito,
  • Cara H. Olsen,
  • Simon D. Pollett,
  • Edward Mitre,
  • Eric D. Laing

摘要

Starting in 2020, we quantified anti-wildtype SARS-CoV-2 spike sera IgG at monthly intervals from generally healthy adults after various doses of mRNA-based COVID-19 vaccination and in the context of hybrid immunity. Confirmed post-vaccination infections and subclinical infections identified by longitudinal serology were removed from vaccine-only analyses. Over 400 days, the two-dose vaccine-alone antibody response decayed at a half-life (t1/2) of 59.8 days compared with a t1/2 of 99.7 days after receipt of one booster dose. In the hybrid immunity model, the t1/2 was greater at 241 days. Using cut-offs for correlation of protection obtained in a prior study, we modeled that individuals with hybrid immunity maintain antibody levels above a 75% correlate of immunity for 283 days after an immune-boosting event. These data offer insights into SARS-CoV-2 antibody decay kinetics that may inform COVID-19 vaccine timing in the younger (age under 60), healthy adult population.